Bulls vs Bears
Click to unlock major analysts' bullish and bearish positions by joining Benzinga Edge.
Comments
Loading...
BioCryst Pharma Analyst Ratings and Price Targets | NASDAQ:BCRX | Benzinga
BioCryst Pharmaceuticals Inc has a consensus price target of $14.3 based on the ratings of 11 analysts. The high is $30 issued by HC Wainwright & Co. on February 25, 2025. The low is $8 issued by Barclays on November 5, 2024. The 3 most-recent analyst ratings were released by Citizens Capital Markets, RBC Capital, and Citizens Capital Markets on March 3, 2025, February 25, 2025, and February 25, 2025, respectively. With an average price target of $15.67 between Citizens Capital Markets, RBC Capital, and Citizens Capital Markets, there's an implied 94.86% upside for BioCryst Pharmaceuticals Inc from these most-recent analyst ratings.
Analyst Firms Making Recommendations1
Citizens Capital Markets
RBC Capital
HC Wainwright & Co.
JMP Securities
Evercore ISI Group
1calculated from analyst ratings
Analyst Ratings for BioCryst Pharma
| Buy Now | Get Alert | |||||||
|---|---|---|---|---|---|---|---|---|
| 03/03/2025 | Buy Now | 123.88% | Citizens Capital Markets | Jonathan Wolleben66% | $18 → $18 | Reiterates | Market Outperform → Market Outperform | Get Alert |
| 02/25/2025 | Buy Now | 36.82% | RBC Capital | Brian Abrahams52% | $10 → $11 | Reiterates | Outperform → Outperform | Get Alert |
| 02/25/2025 | Buy Now | 123.88% | Citizens Capital Markets | Jonathan Wolleben66% | $18 → $18 | Reiterates | Market Outperform → Market Outperform | Get Alert |
| 02/25/2025 | Buy Now | 273.13% | HC Wainwright & Co. | Andrew Fein57% | $30 → $30 | Reiterates | Buy → Buy | Get Alert |
| 01/31/2025 | Buy Now | 123.88% | JMP Securities | Jonathan Wolleben66% | $18 → $18 | Reiterates | Market Outperform → Market Outperform | Get Alert |
| 01/13/2025 | Buy Now | 49.25% | Evercore ISI Group | Liisa Bayko70% | $10 → $12 | Maintains | Outperform | Get Alert |
| 01/13/2025 | Buy Now | 86.57% | Needham | Serge Belanger69% | $14 → $15 | Maintains | Buy | Get Alert |
| 12/17/2024 | Buy Now | 86.57% | Needham | Serge Belanger69% | $14 → $15 | Maintains | Buy | Get Alert |
| 11/05/2024 | Buy Now | 24.38% | RBC Capital | Brian Abrahams52% | $10 → $10 | Reiterates | Outperform → Outperform | Get Alert |
| 11/05/2024 | Buy Now | 74.13% | Needham | Serge Belanger69% | $14 → $14 | Reiterates | Buy → Buy | Get Alert |
| 11/05/2024 | Buy Now | -0.5% | Barclays | Gena Wang50% | $7 → $8 | Maintains | Equal-Weight | Get Alert |
| 08/06/2024 | Buy Now | 99% | JMP Securities | Jonathan Wolleben66% | $15 → $16 | Maintains | Market Outperform | Get Alert |
| 08/06/2024 | Buy Now | -12.94% | Barclays | Gena Wang50% | $6 → $7 | Maintains | Equal-Weight | Get Alert |
| 08/06/2024 | Buy Now | 24.38% | RBC Capital | Brian Abrahams52% | $10 → $10 | Reiterates | Outperform → Outperform | Get Alert |
| 08/06/2024 | Buy Now | 273.13% | HC Wainwright & Co. | Andrew Fein57% | $30 → $30 | Reiterates | Buy → Buy | Get Alert |
| 05/07/2024 | Buy Now | 49.25% | Needham | Serge Belanger69% | $12 → $12 | Reiterates | Buy → Buy | Get Alert |
| 05/07/2024 | Buy Now | 273.13% | HC Wainwright & Co. | Andrew Fein57% | $30 → $30 | Reiterates | Buy → Buy | Get Alert |
| 05/07/2024 | Buy Now | 86.57% | JMP Securities | Jonathan Wolleben66% | $14 → $15 | Maintains | Market Outperform | Get Alert |
| 04/10/2024 | Buy Now | 49.25% | Needham | Serge Belanger69% | $12 → $12 | Reiterates | Buy → Buy | Get Alert |
| 01/08/2024 | Buy Now | 49.25% | Needham | Serge Belanger69% | $12 → $12 | Reiterates | Buy → Buy | Get Alert |
| 11/20/2023 | Buy Now | 24.38% | JP Morgan | Jessica Fye68% | → $10 | Reinstates | → Overweight | Get Alert |
| 11/06/2023 | Buy Now | 49.25% | Needham | Serge Belanger69% | → $12 | Reiterates | Buy → Buy | Get Alert |
| 09/25/2023 | Buy Now | 24.38% | RBC Capital | Brian Abrahams52% | → $10 | Reiterates | Outperform → Outperform | Get Alert |
| 09/18/2023 | Buy Now | 24.38% | RBC Capital | Brian Abrahams52% | $9 → $10 | Upgrade | Sector Perform → Outperform | Get Alert |
| 08/04/2023 | Buy Now | 11.94% | RBC Capital | Brian Abrahams52% | $8 → $9 | Maintains | Sector Perform | Get Alert |
| 08/04/2023 | Buy Now | 36.82% | Jefferies | Maury Raycroft31% | → $11 | Upgrade | Hold → Buy | Get Alert |
| 08/04/2023 | Buy Now | 273.13% | HC Wainwright & Co. | Andrew Fein57% | → $30 | Reiterates | Buy → Buy | Get Alert |
| 08/03/2023 | Buy Now | 49.25% | Needham | Serge Belanger69% | $14 → $12 | Reiterates | → Buy | Get Alert |
| 07/13/2023 | Buy Now | 24.38% | B of A Securities | Tazeen Ahmad55% | → $10 | Upgrade | Neutral → Buy | Get Alert |
| 05/04/2023 | Buy Now | 11.94% | RBC Capital | Brian Abrahams52% | → $9 | Reiterates | → Sector Perform | Get Alert |
| 05/04/2023 | Buy Now | 74.13% | Needham | Serge Belanger69% | → $14 | Reiterates | → Buy | Get Alert |
| 04/20/2023 | Buy Now | 24.38% | Evercore ISI Group | Liisa Bayko70% | $13 → $10 | Maintains | Outperform | Get Alert |
| 04/20/2023 | Buy Now | 74.13% | Needham | Serge Belanger69% | → $14 | Reiterates | → Buy | Get Alert |
| 03/14/2023 | Buy Now | 24.38% | RBC Capital | Brian Abrahams52% | → $10 | Reiterates | → Sector Perform | Get Alert |
| 02/22/2023 | Buy Now | 99% | JMP Securities | Jonathan Wolleben66% | → $16 | Reiterates | → Market Outperform | Get Alert |
| 02/22/2023 | Buy Now | 74.13% | Needham | Serge Belanger69% | → $14 | Upgrade | Hold → Buy | Get Alert |
| 02/22/2023 | Buy Now | 273.13% | HC Wainwright & Co. | Andrew Fein57% | → $30 | Reiterates | → Buy | Get Alert |
| 11/02/2022 | Buy Now | 99% | Evercore ISI Group | Liisa Bayko70% | → $16 | Upgrade | In-Line → Outperform | Get Alert |
| 11/02/2022 | Buy Now | 61.69% | RBC Capital | Brian Abrahams52% | $14 → $13 | Maintains | Sector Perform | Get Alert |
| 08/08/2022 | Buy Now | — | Oppenheimer | Justin Kim37% | — | Downgrade | Outperform → Perform | Get Alert |
| 08/05/2022 | Buy Now | 74.13% | Barclays | Gena Wang50% | $12 → $14 | Maintains | Equal-Weight | Get Alert |
| 08/05/2022 | Buy Now | — | Oppenheimer | Justin Kim37% | — | Downgrade | Outperform → Perform | Get Alert |
| 08/05/2022 | Buy Now | 74.13% | Evercore ISI Group | Liisa Bayko70% | → $14 | Downgrade | Outperform → In-Line | Get Alert |
| 04/18/2022 | Buy Now | 61.69% | Barclays | Gena Wang50% | $22 → $13 | Downgrade | Overweight → Equal-Weight | Get Alert |
| 04/12/2022 | Buy Now | 74.13% | RBC Capital | Brian Abrahams52% | $16 → $14 | Maintains | Sector Perform | Get Alert |
| 04/11/2022 | Buy Now | 74.13% | B of A Securities | Tazeen Ahmad55% | → $14 | Downgrade | Buy → Neutral | Get Alert |
| 04/11/2022 | Buy Now | 99% | Oppenheimer | Justin Kim37% | $20 → $16 | Maintains | Outperform | Get Alert |
FAQ
What is the target price for BioCryst Pharma (BCRX) stock?
The latest price target for BioCryst Pharma (NASDAQ:BCRX) was reported by Citizens Capital Markets on March 3, 2025. The analyst firm set a price target for $18.00 expecting BCRX to rise to within 12 months (a possible 123.88% upside). 19 analyst firms have reported ratings in the last year.
What is the most recent analyst rating for BioCryst Pharma (BCRX)?
The latest analyst rating for BioCryst Pharma (NASDAQ:BCRX) was provided by Citizens Capital Markets, and BioCryst Pharma reiterated their market outperform rating.
When was the last upgrade for BioCryst Pharma (BCRX)?
The last upgrade for BioCryst Pharmaceuticals Inc happened on September 18, 2023 when RBC Capital raised their price target to $10. RBC Capital previously had a sector perform for BioCryst Pharmaceuticals Inc.
When was the last downgrade for BioCryst Pharma (BCRX)?
The last downgrade for BioCryst Pharmaceuticals Inc happened on August 8, 2022 when Oppenheimer changed their price target from N/A to N/A for BioCryst Pharmaceuticals Inc.
When is the next analyst rating going to be posted or updated for BioCryst Pharma (BCRX)?
Analysts arrive at stock ratings after doing extensive research, which includes going through public financial statements, talking to executives and customers of BioCryst Pharma, and listening in to earnings conference calls. Most analysts do this every three months, so you should get 4 ratings per company per firm each year. The last rating for BioCryst Pharma was filed on March 3, 2025 so you should expect the next rating to be made available sometime around March 3, 2026.
Is the Analyst Rating BioCryst Pharma (BCRX) correct?
While ratings are subjective and will change, the latest BioCryst Pharma (BCRX) rating was a reiterated with a price target of $18.00 to $18.00. The current price BioCryst Pharma (BCRX) is trading at is $8.04, which is out of the analyst’s predicted range.
Browse analyst ratings and price targets on all stocks.